In conclusion, miR-200b inhibited GC cell migration and invasion through EMT via the NRG1/ERBB2/ERBB3 signaling pathway, and miR-200b might be a potential biomarker for GC progression, which provides a clue for treating GC. This evidence concerns the gene ERBB3 and gastric cancer.